



12-29-06  
07/508 109

DAC  
IFW

PLEASE CHARGE ANY DEFICIENCY OR CREDIT ANY EXCESS IN THE  
FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO.  
04 - 0100

Customer No.: 07278

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re: U.S. Patent No. 5,061,703  
Inventors: Joachim BORMANN, Markus GOLD, and Wolfgang SCHATTON  
Assignee: Merz Pharma GmbH & Co. KGaA  
Title: ADAMANTANE DERIVATIVES IN THE PREVENTION AND TREATMENT OF  
CEREBRAL ISCHEMIA  
Issue Date: October 29, 1991

-----  
**SUPPLEMENT TO REQUEST FOR EXTENSION OF PATENT TERM**  
**UNDER 35 U.S.C. § 156**

Mail Stop Patent Ext.  
Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This supplement relates to the pending request for extension of the term of U.S. Patent No. 5,061,703 ("the '703 patent") pursuant to 35 U.S.C. § 156, which was submitted on December 9, 2003 by Forest Laboratories, Inc. ("Forest") acting as agent of the patent owner Merz Pharma GmbH & Co. KGaA ("Merz"), and is submitted to indicate that the '703 patent was reexamined by the U.S. Patent and Trademark Office, and a Certificate of Reexamination was issued on November 7, 2006. A copy of the Certificate of Reexamination is attached as Exhibit A.


As a result of the reexamination proceeding, claims 1 and 10 were amended, the patentability of claims 2-9 and 11-13 was confirmed, and claims 14-19 were added.

All information previously provided in the December 9, 2003 Request for Extension of Patent Term Under 35 U.S.C. § 156 remains accurate. In particular, the '703 patent continues to claim a method of using NAMENDA<sup>TM</sup> (memantine hydrochloride), which is approved for the treatment of moderate to severe dementia of the Alzheimer's type, because claim 10 remains explicitly directed to the treatment of Alzheimer's disease and refers to independent claim 1 for the generic formula that continues to encompass memantine hydrochloride, as explained in the December 9, 2003 Request.

Claims 10 and 1 are reproduced below, illustrating the amendments that were made as a result of the reexamination proceeding:

10. A method according to claim 1 for the treatment of Alzheimer's disease, wherein said adamantane derivative is memantine and said effective amount is from about 0.01 to 100 mg/kg.

1. A method for the prevention or treatment of cerebral ischemia comprising the step of orally administering, to a patient diagnosed with Alzheimer's disease and in need thereof, an effective amount of an adamantane derivative of the general formula



wherein

R<sub>1</sub> and R<sub>2</sub> are identical or different and represent hydrogen or a straight or branched alkyl group of 1 to 6 C atoms or, in conjunction with N, a heterocyclic group with 5 or 6 ring C atoms;

wherein

R<sub>3</sub> and R<sub>4</sub> are identical or different, being selected from hydrogen, a straight or branched alkyl group of 1 to 6 C atoms, a cycloalkyl group with 5 or 6 C atoms, and phenyl;

wherein

R<sub>5</sub> is hydrogen or a straight or branched C<sub>1</sub>-C<sub>6</sub> alkyl group; and  
wherein

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> do not all represent hydrogen simultaneously;  
or a pharmaceutically-acceptable salt thereof.

The adamantane derivative of the general formula shown in claim 1 represents memantine hydrochloride when: R<sup>1</sup> and R<sup>2</sup> are hydrogen; one of R<sup>3</sup>, R<sup>4</sup>, and R<sup>5</sup> is hydrogen and the remaining two of R<sup>3</sup>, R<sup>4</sup>, and R<sup>5</sup> are methyl; and the pharmaceutically acceptable salt is the hydrochloride salt. See '703 patent at col. 4, lines 32-37. Additional claims that cover a method for using the approved product include claims 2, 3, 6, 8, and 11-13.

Forest, acting as agent for the patent owner Merz, requests that the Commissioner grant an extension of 1250 days to U.S. Patent No. 5,061,703.

Favorable action is earnestly solicited.

Dated: December 27, 2006

Respectfully submitted,

By 

S. Peter Ludwig

Registration No.: 25,351

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 527-7701 (Fax)

Attorney/Agent for Applicant



Patent No.. (if known): 5,061,703

Attorney Docket No.: 03269/8200177-000

## Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. \_\_\_\_\_ in an envelope addressed to:

**EV 834729838 - US**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on December 27, 2006  
Date



Signature

**LILLIAN GARCIA**

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Supplement To Request For Extension Of Patent Term Under 35 U.S.C. §  
156 (3 pp.)  
Exhibit A (3 pp.)  
Return Receipt Postcard